Literature DB >> 1117287

Anticonvulsants in the treatment of aggression.

R R Monroe.   

Abstract

A significant number of violent acts are committed by individuals in whom central nervous system instability can be demonstrated by special electroencephalographic (EEG) activation procedures utilizing alpha-chloralose as the activating agent. Furthermore, subcortical electrograms suggest that this instability is related to a circumscribed ictal phenomenon in the limbic system. The abruptness of the aggressive act, the fact that the behavior is so often out of character for the individual and inappropriate for the situation, as well as the confusion and partial amnesia which accompany these episodes lend clinical support for the ictal hypothesis. Some anticonvulsants not only block the activated abnormalities on the EEG but also lead to dramatic clinical improvement in those individuals showing repeated and frequent aggressive behavior. For instance, in one study 46.7 percent and 53.3 per cent of the patients demonstrated activated abnormalities on no drug and placebo, respectively. When these same patients were receiving chlorpormazine or trifluoperazine, the activation rates were 60.0 per cent and 73.3 per cent, respectively. On the other hand, when these same patients were placed on a regimen of chlordiazepoxide the activation rate was reduced to 20 per cent (p smaller than or equal to .01). Another study involved severely distrubed chronically hospitalized psychotic patients whose aggressive uncontrolled outbursts relegated then not only to a locked ward, but often to isolation rooms despite high doses of phenothiazines. A regimen of chlordiazepoxide and

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1117287     DOI: 10.1097/00005053-197502000-00006

Source DB:  PubMed          Journal:  J Nerv Ment Dis        ISSN: 0022-3018            Impact factor:   2.254


  10 in total

Review 1.  Antiepileptics for aggression and associated impulsivity.

Authors:  Nick Huband; Michael Ferriter; Rajan Nathan; Hannah Jones
Journal:  Cochrane Database Syst Rev       Date:  2010-02-17

2.  Aggression: psychopharmacologic management.

Authors:  P Conlon; K Frommhold
Journal:  Can Fam Physician       Date:  1989-05       Impact factor: 3.275

Review 3.  Current and Possible Future Therapeutic Options for Huntington's Disease.

Authors:  Mackenzie W Ferguson; Connor J Kennedy; Thulani H Palpagama; Henry J Waldvogel; Richard L M Faull; Andrea Kwakowsky
Journal:  J Cent Nerv Syst Dis       Date:  2022-05-21

Review 4.  An animal model to study the clinical significance of interictal spiking.

Authors:  D T Barkmeier; J A Loeb
Journal:  Clin EEG Neurosci       Date:  2009-10       Impact factor: 1.843

Review 5.  Coma and the etiology of violence, Part 2.

Authors:  C C Bell
Journal:  J Natl Med Assoc       Date:  1987-01       Impact factor: 1.798

Review 6.  The use of carbamazepine in the treatment of schizophrenic and schizoaffective psychoses: a review.

Authors:  C Simhandl; K Meszaros
Journal:  J Psychiatry Neurosci       Date:  1992-03       Impact factor: 6.186

7.  Clinical significance of focal topographic changes in the electroencephalogram (EEG) and evoked potentials (EP) of psychiatric patients.

Authors:  M Gerez; A Tello
Journal:  Brain Topogr       Date:  1992       Impact factor: 3.020

8.  Anticonvulsants in the treatment of aggression in the demented elderly: an update.

Authors:  Benedikt Amann; Johannes Pantel; Heinz Grunze; Eduard Vieta; Francesc Colom; Ana Gonzalez-Pinto; Dieter Naber; Harald Hampel
Journal:  Clin Pract Epidemiol Ment Health       Date:  2009-06-16

9.  Anti-aggressive effects of agonists at 5-HT1B receptors in the dorsal raphe nucleus of mice.

Authors:  Makoto Bannai; Eric W Fish; Sara Faccidomo; Klaus A Miczek
Journal:  Psychopharmacology (Berl)       Date:  2007-04-18       Impact factor: 4.415

10.  Carbamazepine and psychotherapy in the treatment of schizoaffective psychosis.

Authors:  J A Cegalis; S G Possick
Journal:  Yale J Biol Med       Date:  1985 Jul-Aug
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.